Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases

Denosumab is a commonly used antiresorptive treatment in patients with osteoporosis or solid tumours with bone metastases. Upon denosumab discontinuation, a rebound phenomenon can occur that results in an increased (vertebral) fracture risk. This phenomenon is well-known in the setting of osteoporos...

Descripción completa

Detalles Bibliográficos
Autores principales: Dupont, Jolan, Appermans, Wesley, Dejaeger, Marian, Wauters, Isabelle, Laurent, Michaël R., Gielen, Evelien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109183/
https://www.ncbi.nlm.nih.gov/pubmed/35585959
http://dx.doi.org/10.1016/j.bonr.2022.101582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109183/
https://www.ncbi.nlm.nih.gov/pubmed/35585959
http://dx.doi.org/10.1016/j.bonr.2022.101582

Ejemplares similares